What defines a mildly elevated insulin‑like growth factor‑1 (IGF‑1) level and its clinical significance?

What is a Mildly Elevated IGF-1?

A mildly elevated IGF-1 is defined as a level above the age-adjusted, sex-adjusted, and (in children) Tanner stage-matched upper limit of normal but typically less than twice the upper limit of normal, and requires careful interpretation accounting for assay-specific reference ranges and multiple confounding factors before attributing clinical significance. 1, 2

Defining Mild Elevation

• IGF-1 must always be interpreted using age-adjusted and sex-adjusted reference ranges specific to the laboratory assay being used, as IGF-1 physiologically declines substantially with aging and varies between sexes. 1, 2

• In children and adolescents, Tanner stage-matched reference ranges are essential, as IGF-1 levels naturally peak during mid-puberty (Tanner stages 2-3). 2

• Mild elevation typically refers to IGF-1 values less than 2× the upper limit of normal (ULN), as research demonstrates that patients with IGF-1 less than twice the ULN but above the reference range often do not have confirmed acromegaly on oral glucose tolerance testing. 3

• Inter-assay variability is substantial, meaning a value considered elevated on one assay may be normal on another—always use laboratory-specific reference ranges. 1, 2, 4

Critical Confounding Factors That Cause False Elevations

Before attributing clinical significance to a mildly elevated IGF-1, systematically exclude these common causes:

• Poorly controlled diabetes mellitus produces spuriously elevated IGF-1 levels—check HbA1c and fasting glucose. 1, 2

• Hepatic or renal failure may cause falsely elevated IGF-1 measurements—review liver function tests (AST, ALT, bilirubin) and kidney function (creatinine, eGFR). 1, 2

• Substantial week-to-week biological variability exists (unrelated to assay performance), with approximately 65% of patients with initially elevated IGF-1 having normal values on repeat testing after a median follow-up of 36 months. 5, 4

• Assay-specific performance issues contribute to false-positive results in approximately 4% of all IGF-1 measurements. 5

Factors That Cause False-Low IGF-1 (Important for Context)

Understanding what suppresses IGF-1 helps interpret borderline elevations:

• Severe hypothyroidism suppresses hepatic IGF-1 generation—check TSH and free T4. 6, 1, 2

• Malnutrition or energy deficiency directly suppresses IGF-1 production—assess nutritional status, body weight trends, and dietary intake. 6, 1, 2

• Oral estrogen therapy reduces hepatic IGF-1 synthesis through first-pass hepatic metabolism—review medication list for oral contraceptives or hormone replacement. 1, 2

• Severe active infection suppresses the GH-IGF-1 axis—evaluate for acute illness. 1, 2

Clinical Approach to Mildly Elevated IGF-1

Step 1: Verify the Elevation

• Repeat IGF-1 measurement after 1-3 months using the same laboratory assay to account for biological variability and potential spurious results. 5, 4

• Do not compare values across different laboratory assays without understanding assay-specific reference ranges. 1, 2

Step 2: Exclude Confounding Conditions

• Check HbA1c and fasting glucose to rule out poorly controlled diabetes. 1, 2

• Review liver function tests (AST, ALT, bilirubin) and kidney function (creatinine, eGFR) to exclude hepatic or renal failure. 1, 2

• Assess for acute illness or severe infection that may suppress or alter IGF-1 levels. 1, 2

Step 3: Consider Clinical Context

• In the absence of clinical features of acromegaly (coarse facial features, enlarged hands/feet, frontal bossing, prognathism, soft tissue swelling), a mildly elevated IGF-1 alone is insufficient for diagnosis. 3

• An oral glucose tolerance test (OGTT) with growth hormone suppression may be useful to obtain corroborative evidence when there is modest elevation of IGF-1 with absent or equivocal clinical features. 3

• In patients with confirmed acromegaly, IGF-1 less than 1× ULN is the biochemical target of treatment, though newer normative databases have lowered the ULN for middle-aged and elderly individuals compared to historical ranges. 4

Common Pitfalls to Avoid

• Do not use a single universal IGF-1 cutoff across all ages—a value of 251 ng/mL may be normal for a 25-year-old but elevated for a 65-year-old. 1

• Do not assume all elevated IGF-1 values indicate pathology—in adolescents during peak growth spurts, mild elevations may be physiologically appropriate. 2

• Do not immediately pursue extensive workup for a single mildly elevated value—repeat testing first, as 65% normalize spontaneously. 5

• Do not ignore the clinical picture—symptoms, comorbidities, and quality of life should be considered alongside biochemical values when evaluating the need for further investigation. 4

Special Populations

In Patients on Growth Hormone Therapy (e.g., Norditropin, Tesamorelin)

• Target IGF-1 levels within the mid-to-upper portion of the age-adjusted normal range (approximately 0 to +2 SDS) to optimize therapeutic efficacy while minimizing adverse effects. 1, 2

• If IGF-1 is above the age-adjusted range, reduce dose or temporarily discontinue therapy to avoid complications of GH excess. 1

• Recheck IGF-1 every 3-6 months to ensure levels remain within the age-adjusted reference range. 1

In Female Athletes with Low Energy Availability

• Decreased IGF-1 (not elevated) is expected in the setting of relative energy deficiency in sport (RED-S), along with GH resistance. 6

• This context is irrelevant to interpreting mildly elevated IGF-1 but highlights the importance of nutritional assessment when IGF-1 is unexpectedly low. 6

In Children and Adolescents

• A serum IGF-1 below the fifth percentile of the normal range virtually excludes idiopathic growth hormone deficiency but does not rule out organic GHD. 7

• An IGF-1 below the idiopathic short stature (ISS) range is strongly in favor of GHD, after exclusion of poor nutritional status and/or liver disease. 7